Company / SG&A Expense
Yubo International Biotech Ltd SG&A Expense History
FY2015-FY2020 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$29.0K
FY2020
5-year range
$29.0K / $29.0K
FY2016-FY2020
Trend
-39.6%
vs FY2019
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $58,000 to $29,000 over the past 2 years.
Based on SEC 10-K filings.
$29,000 in FY2020 with a 5-year CAGR of -14.4%.
Improved from $58,000 to $29,000 over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -20.6%
- 5-Year CAGR
- -14.4%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -14.4%, indicating a declining trend.
- In FY2020, sg&a expense decreased 39.6% year-over-year.
- Peak sg&a expense was recorded in FY2016.
Company context
Key Data Points
- Altman Z-Score -14.17 (distress zone, below 1.23 threshold)
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2020 | $29.0K | -39.6% |
| FY2019 | $48.0K | -17.2% |
| FY2018 | $58.0K | +0.0% |
| FY2017 | $58.0K | -61.1% |
| FY2016 | $149.0K | +136.5% |
| FY2015 | $63.0K | +34.0% |